Description:BMS-754807 is a small molecule inhibitor primarily known for its role in targeting insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) signaling pathways. It has been investigated for its potential therapeutic applications in various cancers and metabolic disorders due to its ability to disrupt the IGF signaling axis, which is often implicated in tumor growth and survival. The compound exhibits a moderate to high affinity for its targets, leading to inhibition of downstream signaling pathways that promote cell proliferation and survival. BMS-754807 is typically characterized by its chemical structure, which includes specific functional groups that contribute to its biological activity. In preclinical studies, it has shown promise in reducing tumor growth in certain cancer models. However, like many investigational drugs, its safety and efficacy in humans are still under evaluation, and it may have associated side effects that need to be carefully monitored during clinical trials. Overall, BMS-754807 represents a significant area of research in targeted cancer therapies.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![(S)-1-(4-((5-Cyclopropyl-1H-Pyrazol-3-Yl)Amino)Pyrrolo[2,1-F][1,2,4]Triazin-2-Yl)-N-(6-Fluoropyrid…](https://static.cymitquimica.com/products/54/thumb/PC108736.jpg)
